TIBER CREEK GROUP

Lobbying for PHRMA

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Sep 30, 2025.

Filing Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 18, 2025

Income

$120,000.00

What the client paid this registrant for the period.

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform.

Trade (domestic/foreign)

Issues related to intellectual property protections.

Health Issues

Issues related to the 340B Program - Public Health Service Act (PL 78-410).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.